EICHOR
● Recruiting
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Condition: B-ALL · Sponsor: Zhejiang University
About this study
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
This description comes directly from the study's public registry record.
Talk to the study team
He Huang, MD · 057187233772 · hehuangyu@126.com
Yongxian Hu, MD · 057187233772 · huyongxian2000@aliyun.com
Always discuss trial participation with your own doctor first.
Locations (1)
| First Affiliated Hospital of Zhejiang University | Hangzhou, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07246707